These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11066505)

  • 1. Medical malpractice implications of PSA testing for early detection of prostate cancer.
    Collins MM; Fowler FJ; Roberts RG; Oesterling JE; Annas GJ; Barry MJ
    J Law Med Ethics; 1997; 25(4):234-42, 230. PubMed ID: 11066505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Status of PSA determination for early detection of prostate carcinoma].
    Hammerer P; Huland H
    Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA and prostate cancer diagnosis.
    Savage P; Waxman J
    Eur J Cancer; 1996 Jun; 32A(7):1097-9. PubMed ID: 8758236
    [No Abstract]   [Full Text] [Related]  

  • 4. [Significance of the PSA-concentration for the detection of prostate cancer].
    Stachon A
    Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.
    Hayat Roshanai A; Nordin K; Berglund G
    Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PSA-based early detection of prostate cancer].
    Luboldt H; Rübben H
    Urologe A; 2000 Jan; 39(1):22-6. PubMed ID: 10663192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen screening: An update of physician beliefs and practices.
    Hall IJ; Rim SH; Massetti GM; Thomas CC; Li J; Richardson LC
    Prev Med; 2017 Oct; 103():66-69. PubMed ID: 28793236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Additional aids in detection of prostate carcinomas? PSA-prostatic volume quotient, PSA-doubling time, age-dependent PSA reference values and PSA in urine].
    Pannek J; Brands FH
    Urologe A; 2000 Jul; 39(4):324-9. PubMed ID: 10957773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.
    Wolff JM; Scholz A; Boeckmann W; Jakse G
    Eur Urol; 1994; 25(4):295-8; discussion 304. PubMed ID: 7519991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].
    Giménez N; Filella X; Gavagnach M; Allué JA; Pedrazas D; Ferrer F;
    Semergen; 2018 Sep; 44(6):409-419. PubMed ID: 29574008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate Specific Antigen (PSA), yet how much damage?].
    Braillon A; Hill C; Dubois G
    Presse Med; 2012 May; 41(5):482-5. PubMed ID: 22336482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Care Physicians Beliefs about Prostate-Specific Antigen Evidence Uncertainty, Screening Efficacy, and Test Use.
    Ross LE; Hall IJ; Howard DL; Rim SH; Richardson LC
    J Natl Med Assoc; 2018 Oct; 110(5):491-500. PubMed ID: 30129508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians.
    Austin OJ; Valente S; Hasse LA; Kues JR
    Arch Fam Med; 1997; 6(5):453-8. PubMed ID: 9305688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
    Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
    Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
    Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
    Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA testing for men at average risk of prostate cancer.
    Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
    Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA and the detection of prostate cancer.
    Robbins AS
    JAMA; 1994 Jan; 271(3):192-3. PubMed ID: 7506314
    [No Abstract]   [Full Text] [Related]  

  • 20. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia.
    Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
    Am J Med; 1998 Jun; 104(6):517-25. PubMed ID: 9674713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.